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Abstract 
Background: Prophylactic and therapeutic vaccines often depend upon a strong activation of the innate immune 
system to drive a potent adaptive immune response, often mediated by a strong adjuvant. For a number of adjuvants 
immunological readouts may not be consistent across species.
Methods: In this study, we evaluated the innate immunostimulatory potential of mRNA vaccines in both humans 
and mice, using a novel mRNA‑based vaccine encoding influenza A hemagglutinin of the pandemic strain 
H1N1pdm09 as a model. This evaluation was performed using an in vitro model of human innate immunity and 
in vivo in mice after intradermal injection.
Results: Results suggest that immunostimulation from the mRNA vaccine in humans is similar to that in mice and 
acts through cellular RNA sensors, with genes for RLRs [ddx58 (RIG‑1) and ifih1 (MDA‑5)], TLRs (tlr3, tlr7, and tlr8‑human 
only), and CLRs (clec4gp1, clec2d, cledl1) all significantly up‑regulated by the mRNA vaccine. The up‑regulation of TLR8 
and TLR7 points to the involvement of both mDCs and pDCs in the response to the mRNA vaccine in humans. In both 
humans and mice activation of these pathways drove maturation and activation of immune cells as well as produc‑
tion of cytokines and chemokines known to attract and activate key players of the innate and adaptive immune 
system.
Conclusion: This translational approach not only allowed for identification of the basic mechanisms of self‑adju‑
vantation from the mRNA vaccine but also for comparison of the response across species, a response that appears 
relatively conserved or at least convergent between the in vitro human and in vivo mouse models.
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Background
Despite evidence demonstrating that predictive immuno-
logical parameters may not be applicable across species, 
preclinical assessments of vaccines or vaccine adjuvants 
still typically rely on mouse models as the experimental 
tool of choice [1, 2]. Significant differences have been 
demonstrated between mouse and human immune sys-
tem development, activation and response to challenge 
[2–5]. These differences have led to failure in clinical tri-
als of formulations that appeared promising in preclinical 
studies [2–6]. Because a mouse cannot be considered a 
“small human” the development of better methods for the 
study and analysis of human-based immune system mod-
els has been identified as an area of critical need in vacci-
nology. The need for human-based methods has begun to 
be filled with the continued development in vitro assays 
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immune system [9, 10], both of which show promise 
but neither of which are currently widely used. Human-
based in vitro models may not always replicate the entire 
immunomodulatory activity of an adjuvant or vaccine 
and are thus a logical complement to in vivo studies [1]. 
This combination of in  vitro and in  vivo models offers 
the opportunity to identify cellular receptors and path-
ways that are conserved between mice and humans as 
well as species-specific differences in innate and adaptive 
immune response to vaccines and vaccine adjuvants.
New in  vitro technologies for the pre-clinical assess-
ment of innate response to vaccines or adjuvants have 
been developed. These include new human-based 
assays that utilize human monocytoid cell lines or pri-
mary immune cells to detect the innate response and 
safety profile of pyrogens, toxic compounds, adjuvants, 
and vaccines [11–15]. One such model, the Modular 
Immune In  vitro Construct (MIMIC®), models human 
innate and adaptive immunity in a sensitive, automated, 
and cost-effective manner [16]. Two distinct modules 
of the MIMIC®, the Peripheral Tissue Equivalent model 
(PTE) and Transwell Peripheral Tissue Equivalent model 
(TW-PTE), are biomimetic modules designed to simu-
late innate immune response as it occurs in peripheral 
tissues such as the skin following an encounter with 
a vaccine or a pathogen, and can be used to examine 
human responses against vaccines or vaccine adjuvants. 
They utilize primary human immune cells coupled with 
naturally occurring signaling processes to replicate the 
development of cells responsible for much of the innate 
immune response. These modules have been shown to 
reflect appropriate cellular profiles (programmed death, 
cytokine production, and antigen presenting cell activa-
tion/maturation) following stimulation by a variety of test 
agents including monoclonal antibodies (e.g. TGN1412), 
seasonal influenza vaccines, immunomodulators and 
immunosuppressants such as TLR agonists and cyclo-
sporine, respectively [11, 13, 16–19]. Genome-wide tran-
scriptome analysis represents an additional tool for the 
evaluation of innate response to vaccines or vaccine adju-
vants, providing a signature of innate immune response 
to various challenges [1, 20–22]. Molecular signatures in 
the blood of humans induced a few days after vaccination 
have been used to predict the magnitude of later immune 
responses to a vaccine and are beginning to yield insights 
about the nature of the innate and adaptive responses to 
vaccination [23–25]. Additionally, in the vein of transla-
tional science, this technology can be applied to the eval-
uation of vaccine adjuvants in pre-clinical assessments 
including both in  vivo models [e.g. murine, non-human 
primates (NHP)] and in vitro models (e.g. MIMIC®), the 
results of which have direct applications to later clinical 
evaluations in humans.
In recent years researchers have begun developing new 
classes of vaccine adjuvants which target natural innate 
response pathways in immune cells. These include com-
pounds targeting pattern recognition receptors (PRRs) 
such as the TLRs and RLRs. PRR agonists have garnered 
considerable interest in recent years based on their ability 
to activate an immune response in a manner consistent 
with that triggered by invading pathogens. For example, 
the use of the synthetic ligand CpG (a TLR9 agonist) 
co-administered with various protein antigens has been 
investigated in a number of preclinical trials, and shown 
to induce potent antigen-specific responses [26–29]. 
Activation of PRRs leads to downstream activation of 
transcription factors resulting in expression of various 
genes that drive immune cell maturation, expression of 
co-stimulatory molecules and production of cytokines 
and chemokines [30–38]. Viral single-stranded RNA 
(ssRNA) and double-stranded RNA (dsRNA) are among 
the many PRR-selective agonists binding and activating 
TLRs, RLRs, and CLRs in cellular membranes, endoso-
mal compartments, and inside the cell through cyto-
plasmic sensors [32–34, 38]. Species-specific response 
to ssRNA from human immunodeficiency virus (HIV) 
has been demonstrated between mice and human, with 
murine TLR7 and human TLR8 mediating recognition 
of GU-rich ssRNA, respectively [31, 33]. In both mouse 
and human, however, responses to ssRNA and dsRNA 
through TLRs and RLRs converge on NF-κB and mito-
gen-activated protein kinase signaling pathways, includ-
ing the TLR, interleukin (IL)-1, and c-jun N-terminal 
kinase (JNK) pathways [32]. Activation of these pathways 
in multiple immune cell subsets including pDCs, mDCs, 
monocytes, B-cells, and T-cells results in up-regulation 
of innate stimulation pathways [30–37].
Synthetic nucleic acids vaccines are being investi-
gated as alternatives to traditional vaccines. When used 
as vaccines nucleic acids have the potential to not only 
trigger an immunogenic response to the antigens they 
encode but also to trigger innate sensors of ribonucleic 
acid (RNA) or deoxyribonucleic acid (DNA) in immune 
cells. Although DNA-based vaccines have been inves-
tigated for use in molecular medicine and vaccinology, 
clinical applications have increasingly become compro-
mised based on the efficacy and potential risks inher-
ent in use of plasmid DNA. As an alternative to DNA, 
mRNA based vaccines have been developed to take 
advantage of the fact that mRNA molecules have the 
ability to transiently encode immunogenic antigens and 
also possess self-adjuvanting activity [39]. A new class of 
mRNA vaccines, RNActive® vaccines, is based on con-
ventional mRNA molecules that have been engineered 
and sequence-modified to optimize various aspects of 
the molecule, leading to enhanced mRNA half-life and 
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protein expression [40]. An important building block 
for the formulation of RNActive® vaccines is protamine, 
a cationic peptide that forms complexes with RNA. 
RNActive® vaccines containing protamine consists 
of an engineered mRNA, which in part is complexed 
with protamine. This formulation combines the strong 
expression profile of optimized mRNA with enhanced 
immune stimulation induced by protamine-complexed 
mRNA reported to activate the TLR7 receptor [40–43]. 
This self-adjuvant activity has been investigated in pre-
clinical animal studies as well as in clinical safety inves-
tigations for both therapeutic cancer and prophylactic 
vaccines [40, 42–46].
In the present study, we applied a combined series of 
analytical techniques which constituted an original trans-
lational approach to a pre-clinical assessment of the basic 
mechanisms of self-adjuvantation from mRNA vaccines 
in an in vitro human model and in vivo in inbred mice. 
We used the in  vitro model of the human immune sys-
tem termed the MIMIC® to evaluate innate responses 
induced by distinct doses of the mRNA vaccine encod-
ing influenza A hemagglutinin (HA). These responses 
were compared to profiles found in C57 BL/6-mice 
after intradermal injection. The murine samples were 
taken from two locations, at the injection site and in the 
draining lymph node (dLN). Phenotypic alterations of 
immune stimulatory cells and cytokine response in both 
the MIMIC® and in the mice were analyzed and com-
pared. In each case an analysis of transcriptional changes 
was also performed, with activation pathways evaluated 
to compare gene expression profiles in both the human 




This study was designed to evaluate the innate stimula-
tory profiles and basic mechanisms of self-adjuvanta-
tion of an mRNA-based vaccine encoding influenza A 
hemagglutinin in humans and inbred C57BL/6 mice. For 
all three phases of this study an mRNA vaccine encod-
ing influenza A hemagglutinin of the pandemic strain 
H1N1pdm09 from the isolate A/Netherlands/602/2009 
was used as the model [43, 45]. The first study phase 
consisted of experiments on MIMIC®-PTE modules to 
assess the adjuvant properties of different concentrations 
of mRNA vaccine versus a benchmark vaccine (Fluzone®, 
Sanofi Pasteur) and the TLR7/8 agonist R848. These 
experiments were designed to test the immunostimula-
tory potential of these treatments in humans through the 
use of the human MIMIC® system to establish associated 
phenotypic and cytokine profiles. The second study phase 
was an analysis of transcriptome changes in humans in 
response to immunostimulation with the mRNA vac-
cine or R848 as a positive control of TLR7/8 activation. 
For this study the human MIMIC® Transwell-PTE mod-
ule was used to generate RNA samples for use in full 
genome microarray analysis. The third and final phase of 
this work was performed in wild type mice to assess the 
mechanisms of self-adjuvantation from the mRNA vac-
cine by evaluation of cellular and molecular sensors at 
the injection site and in the dLN. To perform this analy-
sis of gene expression patterns a full genome microarray 
analysis was performed on skin biopsies or the dLN after 
intradermal injection of the mRNA vaccine.
Preparation of peripheral blood mononuclear cells 
for MIMIC®
Apheresis blood products were collected from 30 donors 
(phase 1 study: 24 donors; phase 2 study: 6 donors). 
The collections and study protocol were reviewed and 
approved by Chesapeake Research Review Inc (Colum-
bia, Maryland) under IRB 0906009, “Development and 
testing of the MIMIC®”. All donors were screened and 
reported to be in good health. All blood products were 
received and confirmed to be negative for blood-borne 
pathogens as detected by standard blood bank screening 
assays.
Peripheral blood mononuclear cells (PBMCs) were 
enriched by Ficoll density gradient separation accord-
ing to standard laboratory procedures [47]. After 
washing, PBMCs were cryopreserved in dimethyl sul-
foxide-containing freezing media for extended storage in 
liquid nitrogen. Donor PBMCs were chosen at random 
from our pool for inclusion in this study. In phase 1, 12 
“Adult” donors of age <50 years and 12 “Elderly” donors 
of age ≥65  years were included. All donors for phase 2 
were less than 50 years in age.
MIMIC® Peripheral Tissue Equivalent Assay (phase 1 study)
The PTE construct of the MIMIC® system is designed 
to replicate the early responses of innate immunity 
(cytokines and antigen presenting cell activation/matu-
ration) in response to test agents [11, 13, 16, 17]. The 
MIMIC® PTE module used in this study was built around 
our published manual technique but automation was 
used for cell and treatment application and washing 
steps [13]. Briefly, endothelial cells were grown to a con-
fluent layer atop a collagen matrix (PureCol; Advanced 
Biomatrix, San Diego, California). Thereafter, donor 
PBMCs were prepared from frozen stocks and applied 
to MIMIC® PTE assay wells. After an incubation period, 
non-migrated cells were washed away leaving only those 
cells that had transmigrated across the endothelial barrier 
into the collagen matrix. Over the course of a 48-h incu-
bation period, antigen presenting cells (APCs), primarily 
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differentiating immature dendritic cells, reverse-trans-
migrate back across the endothelial barrier (Additional 
file 1: Fig. S1). Test agents including mRNA vaccine were 
added to the constructs at the indicated concentrations 
24 h prior to cell collection. MIMIC®-PTE modules were 
left untreated or treated with increasing concentrations 
of the mRNA vaccine (5–50  μg/106 cells), benchmark 
influenza vaccine (Fluzone® Trivalent 2012–13, FZ, 
1:100), or the TLR7/8 agonist R848 (5 μg/ml). 24 human 
donors were assessed.
The reverse transmigrated cells were harvested after 
the 48-h incubation period for phenotyping analysis by 
flow cytometry. The cells were harvested, washed, and 
labeled for viability with LIVE/DEAD Aqua (Invitrogen, 
Eugene, Oregon). The cells were then labeled with a mul-
ticolor antibody panel specific for cluster of differentia-
tion (CD) 14, human leukocyte antigen-DR, lymphocyte 
markers (CD3/CD19), and markers of immune cell acti-
vation/maturation (CD86, CD40, CCR7, CD25). All anti-
bodies were purchased from eBiosciences (San Diego, 
California) or BD/Biosciences (San Jose, California). 
Data was acquired on a BD FORTESSA II flow cytometer 
(BD/Biosciences) and analyzed using FlowJo software 
(TreeStar Inc, Ashland, Oregon). Culture supernatants 
of MIMIC® PTE assays were also analyzed by multiplex 
bioplex analysis for cytokines and chemokines involved 
in innate immune cell activation and response [Millipore 
MILLIPLEX® human cytokine/chemokine kit(s)]. Levels 
of cytokines were measured in the pg/ml range, allowing 
for comparison of treated immune cell versus untreated 
control PTE wells.
MIMIC® Transwell Peripheral Tissue Equivalent Assay 
(phase 2 study)
As with the MIMIC® PTE construct, the MIMIC® Tran-
swell PTE construct is also designed to replicate the early 
processes of innate immunity in response to test agents, 
albeit in a larger-scale manner [47]. In this system, 
endothelial cells were grown to a confluent layer atop a 
transwell membrane. Thereafter, donor PBMCs were pre-
pared from frozen stocks and applied to MIMIC® TW-
PTE assay wells. After an incubation period the bucket 
containing the non-migrated cells was removed leav-
ing only those cells that had transmigrated across the 
endothelial barrier into the bottom transwell bucket. As 
in the MIMIC® PTE constructs, these cells were primar-
ily composed of differentiating immature dendritic cells 
and a small population of leukocytes comprised of B-cells 
(1–5%) and T-cells (15–20%) and were cultured for 48 h 
before collection. 24 h prior to collection the mRNA vac-
cine was added to the TW-PTE modules at 25  μg/106 
cells. As a positive control, 5  μg/ml R848 was added to 
the constructs.
Use of the larger-scale MIMIC® TW-PTE system 
allowed for the collection of enough cells for RNA iso-
lation and purification for use in full genome microar-
ray analysis, all while retaining the cell populations and 
innate response profile found in MIMIC® PTE modules.
Biopsy of mouse injection sites (phase 3 study)
The mRNA vaccine was applied via intradermal injec-
tion, distributed to two sites on the backs of C57BL/6 
mice. 2 ×  50  μl of mRNA vaccine dissolved in Ringer’s 
lactate solution were injected, for a total amount of 
80  μg of mRNA vaccine. Biopsies were collected 6 or 
24 h post treatment from the injection site (two approx. 
1 cm2 pieces per mouse) and the dLN (axillary and bra-
chial, four dLN in total). The time points of analysis were 
selected so that earlier (6 h) and later (24 h) effects could 
be measured. Animals treated with buffer served as con-
trols. Untreated mice were used as an additional control 
to exclude the possibility of unspecific effects induced by 
the injection of the buffer. The animal protocol (CUR6-
12) was approved by the regional council in Tuebingen, 
Germany.
RNA samples from MIMIC® TW‑PTE (phase 2 full genome 
microarray analysis)
24  h after treatment, MIMIC® TW-PTE donor sam-
ples (n = 18) were collected and the cells were counted. 
Briefly, following harvest from the PTE at least 1 ×  106 
immune cells, composed primarily of immature dendritic 
cells with a small subset of T-cells and B-cells, were lysed 
in Buffer RLT (QIAGEN) with freshly added 2-mercap-
toethanol and stored at −80 °C. After all time points were 
collected, the samples were thawed, and the RNA isola-
tion proceeded according to the manufacturer’s protocol 
(QIAGEN). Total RNA sample quality was evaluated by 
spectrophotometer to determine quantity, protein con-
tamination and organic solvent contamination, and an 
Agilent 2200 Tapestation was used to check for RNA 
degradation. Two-round in  vitro transcription ampli-
fication and labeling was performed starting with 50 ng 
intact, uncontaminated total RNA per sample, following 
the Affymetrix protocol. After hybridization on Human 
U133 Plus 2.0 Arrays for 16 h at 45 °C and 60 r.p.m. in a 
Hybridization Oven 640 (Affymetrix), slides were washed 
and stained with a Fluidics Station 450 (Affymetrix). 
Scanning was performed on a seventh-generation Gene-
Chip Scanner 3000 (Affymetrix), and Affymetrix GCOS 
software was used to perform image analysis and gener-
ate raw intensity data. Initial data quality was assessed by 
background level, 3′ labeling bias, and pairwise correla-
tion among samples. For this analysis, we used Affym-
etrix Human Genome U133 Plus 2.0 Array, but instead 
of using Affymetrix’s sequence clusters to define genes, 
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which is based on the UniGene database build 133, 20 
April 2001, gene sequence clusters were based on the 
updated UniGene build 199, 16 January 2007, to yield a 
list of 20,078 genes.
Microarray analysis (phase 2 full genome microarray 
analysis)
Gene expression data was analyzed using Array Studio 
(Omicsoft, V7.2). The data was normalized and a MAS5 
report was generated for QC assessment. The ArrayStu-
dio (V7.2), Ingenuity Pathway Analysis (IPA, http://www.
ingenuity.com) and GeneGo (Thomson Reuters, Meta-
Core version 6.19, build 65960) packages were used to 
identify differentially expressed genes (pFDR < 0.05; fold 
change >1.3 and <−1.3) compared with mock condition.
Data processing and statistical analysis (phase 2 full 
genome microarray analysis)
Initial quality control of the microarray signal intensity 
data was performed using the lumi Bioconductor pack-
age [48] in the R programming language. Regression and 
ANOVA were carried out in R. Further analysis was car-
ried out using ArrayStudio. Array Studio, Array Viewer 
and Array Server and all other Omicsoft products or 
service names are registered trademarks or trademarks 
of Omicsoft Corporation, Research Triangle Park, NC, 
USA. Statistical analysis was performed using the SAS 
environment package JMP® (JMP®,Version 10. SAS Insti-
tute Inc., Cary, NC, 1989–2007).
Pathway enrichment and content analysis (phase 2 full 
genome microarray analysis)
The gene ontology vocabulary used was obtained from 
the GO Web site (http://www.geneontology.org, 2014 
build). Genes that had shown to be significantly modu-
lated by vaccination, as determined by the microarray 
analysis were further analyzed for pathway enrichment. 
Briefly, we used ArrayStudio to analyze the microarray 
data by pairwise scatter analysis and identify significantly 
differentially regulated genes. The differentially expressed 
genes were defined in terms of the log2-fold change for 
treatment over mock. To limit the detection of false posi-
tives, the array data was set with thresholds including p 
values adjusted by the Benjamini and Hochberg false-
discovery-rate method with a cutoff of 0.05. Gene lists 
were analyzed using GenGo MetaCore analysis software 
(Thompson Reuters), Ingenuity Pathway Analysis soft-
ware (Ingenuity Systems) and DAVID Ontology (http://
www.david.abcc.ncifcrf.gov) to identify significantly asso-
ciated pathways and generate pathway maps.
Phase 3 full genome microarray analyses from mouse 
tissue biopsies
Total RNA was isolated from RNAlater-preserved biopsy 
tissues with commercially available kits and gene expres-
sion analysis was performed by the service provider 
MFT Tuebingen, Germany. For this purpose 100  ng of 
total RNA was amplified per array with the Ambion WT 
expression kit according to the manufacturer instruc-
tions and labeled. The samples were then hybridized 
and stained on the Affymetrix WT Mouse Gene-2.1-ST 
GeneChip Array using the Affymetrix hybridization, 
wash, and stain kit. The arrays were scanned with the 
Affymetrix GCS3000 reader. The raw data were read in 
the AGCC 3.0 software and converted to intensity values. 
Further analysis of the data was performed in R 2.15.1 
on various Bioconductor packages. Some arrays did not 
meet the quality control criteria (one skin sample from 
group 4, one skin sample from group 5 and one dLN 
sample from group 3 and were excluded from further 
analysis. Since at least four replicates per condition were 
still available, the impact on the statistical analysis should 
be considered as very low.
To identify differentially expressed transcripts the 
arrays were normalized via RMA (Robust Multichip 
Average) [49]. All subsequent steps were separated by 
tissue. For the calculation of differentially expressed 
transcripts a linear model was created for the com-
parisons of the mRNA vaccine treated groups and the 
respective buffer controls. Before fitting the model 
control probes were removed and a non-specific vari-
ance filter was applied to eliminate non informative 
transcripts. Subsequently, the coefficients of the linear 
model that describes the expression profile of the cor-
responding gene were calculated based on the experi-
mental design [50]. The relevant comparisons were 
defined as a contrast matrix and the F-statistic was 
calculated for all comparisons, with the standard error 
moderated through an empirical Bayesian model [51]. 
Subsequently, to receive a statement about the signifi-
cance of the comparisons the p value resulting from 
the F-statistic was determined and corrected via “Ben-
jamini–Hochberg” for multiple testing for all tran-
scripts followed by a decision matrix [52]. Similarly, 
the strength of the change in expression (M value) was 
determined. The M value is the log2 of the fold change. 
Because many transcripts were differentially regulated 
only transcripts with a corrected p value less than 0.01 
and a log2 fold change greater than 0.9 (fold change 
greater than 1.87) were taken into account for the sub-
sequent analysis.
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Statistical analysis
All statistical analyses and graphics were prepared using 
GraphPad InStat version 46.00 (GraphPad Software 
Inc, San Diego, California). One-way analysis of vari-
ance (ANOVA) and Bonferroni posttest analyses were 
employed to determine statistical significance; p values 
<0.05 were considered statistically significant.
Results
Dose‑driven innate response to mRNA vaccine stimulation 
in human MIMIC®‑Peripheral Tissue Equivalent Assay
The purpose of the first phase of this study was to eval-
uate the immune-stimulatory potential of different 
concentrations of mRNA vaccine in humans. Human 
cell-based MIMIC®-PTE modules were used and were 
either left untreated or were treated with benchmark 
influenza vaccine (Fluzone®, 2012–13), the TLR7/8 ago-
nist R848, or 6 increasing concentrations of mRNA vac-
cine (5–50  μg/106 cells). 24  h after the application of 
treatment human immune cells were harvested from the 
modules and analyzed for phenotypic markers associated 
with activation using conventional flow cytometry. Only 
the reverse-transmigrated cells (those recovered from 
the media above the endothelial cell layer) were included 
in this evaluation (Additional file  1: Fig. S1), with the 
immune cell populations typically comprised of 80–90% 
APCs, 10–15% CD3+ T-cells, and 1–5% CD19+ B-cells. 
Culture supernatant was also collected and analyzed by 
multiplex bioplex analysis for cytokines and chemokines 
involved in innate immune cell activation and response. 
Levels of cytokines were measured in the pg/ml range, 
allowing for comparison of treated versus untreated 
MIMIC®-PTE modules.
Cell viability assessments were performed on reverse 
transmigrated cells, including both APC and leukocyte 
sub-populations. Figure 1a shows the impact of the vari-
ous treatments on cell viability, activation and cytokine 
production. There was a dose dependent reduction in 
cell recovery following treatment with mRNA vaccine, an 
effect that was most pronounced in the APC cell popu-
lation (Additional file  2: Fig. S2). Over the dose range 
examined (5–50 μg/106 cells) the number of HLA-DR+ 
cells recovered dropped substantially while leukocyte 
numbers dropped only slightly (Additional file  2: Fig. 
S2A, B), indicating greater sensitivity of HLA-DR+ APCs 
for stimulation following mRNA uptake. The impact of 
treatment with a TLR 7/8 agonist, R848 at 5 μg/ml, also 
caused a decrease in live cell recovery in the APC popu-
lation that was equivalent to the highest dose of mRNA 
vaccine.
Antigen presenting cells respond vigorously to a num-
ber of various stimuli such as TLR agonists, antigen, or 
virus [7, 8, 11, 13, 33, 35, 53]. Mature activated APCs are 
characterized by expression of markers such as CD14low/
CCR7high/HLA-DRhigh/CD40high/CD80high/CD86high. 
Reverse-transmigrated cells generated in the MIMIC®-
PTE were characterized using flow cytometry to ana-
lyze the effect on phenotypic markers of activation of 
the treatments on APC maturation and activation. As a 
positive control the TLR 7/8 agonist R848, known to be a 
highly potent innate stimulus, was shown to trigger APC 
maturation as evidenced by the down-regulation of CD14 
and the up-regulation of HLA-DR (Fig.  1b; Additional 
file 3: Fig. S3). The mRNA vaccine caused a dose-depend-
ent maturation effect in APCs as evidenced by the up-
regulation of HLA-DR (expression level as measured by 
geometric mean fluorescence intensity, GMFI) an effect 
that plateaued at the 20 μg/106 cells dose.
Following reverse transmigration in the MIMIC®-PTE 
module immune cells can potentially be “activated” by 
innate immune stimuli such as TLR signaling [35, 53]. In 
APCs and leukocytes a number of surface markers are 
indicative of the cell’s activation status. These include 
CD25, CCR7, CD40, and the co-stimulatory molecule 
CD86. PTE-derived APCs and B-cells were activated by 
both R848 and mRNA vaccine in a dose-dependent man-
ner. The expression of the co-stimulatory molecule CD86 
was greatly enhanced at higher doses of mRNA vaccine 
in the B cell population and at intermediate doses in 
the APCs, with maximal expression of CD86 at a dose 
of 10  μg/106 cells and declining slightly at higher doses 
(Fig. 1c, d). Expression of CCR7, CD25, and CD40 were 
also up-regulated by treatment with both compounds 
(APC profiles shown in Additional file 4: Fig. S4) but were 
most strongly up-regulated at higher doses of mRNA 
vaccine.
The mRNA vaccine’s ability to activate MIMIC®-PTE 
cells to produce cytokines and chemokines with known 
immune or inflammatory properties was evaluated 
using the supernatants collected following stimulation. 
Cytokine production was evaluated at doses ranging 
from 5 to 50 μg/106 cells and compared to the levels gen-
erated following stimulation with the TLR 7/8 agonist 
R848 at 5 μg/ml. Sentinel markers for innate immune cell 
activation by TLR ligands include IL-12(p70) and TNF-α 
(Fig. 1e, f ) as well as IFN-α, IL-12(p40), and IL-6 (Addi-
tional file  5: Fig. S5). There was a clear dose-dependent 
increase in the production of these cytokines by mRNA 
vaccine. Levels of each cytokine also increased after 
treatment of PTE constructs with R848, indicative of 
Page 7 of 18Edwards et al. J Transl Med  (2017) 15:1 
activation of similar signaling pathways to those seen for 
the mRNA vaccine.
Shared activation profile from mRNA vaccine and R848 
stimulation in human subjects (MIMIC®)
A genome-wide transcriptome analysis has been shown 
to be useful to identify gene signatures which predict 
immunogenicity of a number of vaccines in humans [22]. 
In the second phase of this study, we used the Affymetrix 
gene chip U133A+ to evaluate activation pathways in 
MIMIC® TW-PTE derived innate immune cells, primar-
ily composed of differentiating immature dendritic cells 
and a small population of leukocytes comprised of B-cells 
(1–5%) and T-cells (15–20%). RNA was extracted 24  h 
after treatment with the mRNA vaccine or R848 con-
trol, purified, and analyzed. Gene expression analysis was 
performed on both mRNA and R848-treated MIMIC® 
Transwell-PTE modules, with resulting expression val-
ues normalized versus untreated “no antigen” control 
modules. As shown in Fig. 2a numerous transcripts were 
differentially regulated following both treatments and 
the transcriptional response was strongly correlative 
between the two treatments (Fig. 2b–d). This correlation 
was evident when evaluating the entire transcriptome 
(Fig.  2b), all differentially expressed genes (Fig.  2c), and 
an immune-related gene subset (Fig.  2d) that includes 
the following gene categories: chemokines, cytokines, 
antigen presentation, mannose receptors, TLRs, CLRs, 
major histocompatibility complex class 1 and 2 (MHC), 
and other miscellaneous immune-related genes. The 
hierarchical clustering of these significant differentially 
expressed genes is shown in Fig. 2e. The immune-related 
gene subset that showed correlation in Fig. 2d is listed on 
a gene by gene basis in Fig. 3. The majority of genes listed 
display common patterns of regulation.
Of particular interest in this transcriptional analysis 
was the identification of PRR’s up-regulated after mRNA 
vaccine stimulation and the identification of immune-
related pathways that were most significantly activated. 
Genes for RLRs [ddx58 (RIG-1) and ifih1 (MDA-5)], 
TLRs (tlr3, tlr7, and tlr8), and CLRs (clec4gp1, clec2d, 
cledl1) were all significantly activated by the mRNA vac-
cine (Fig. 3), generating a response profile characteristic 
of dsRNA or ssRNA-receptor binding. R848, specifically 
indicated as an agonist for TLR7/8, did not strongly 
induce TLR3 where the mRNA vaccine did. This activa-
tion of TLR3 and RLRs is suggestive of double-stranded 
structures in the mRNA vaccine. Additionally, this 
Fig. 1 Dose‑driven innate response in MIMIC®‑PTE. Dose‑driven innate response in MIMIC®‑PTE immune cell populations to the mRNA vaccine, 
response that is similar to that of the TLR 7/8 agonist resiquimod (R848, 5 μg/ml). The benchmark influenza vaccine Fluzone (FZ) was also evalu‑
ated. a Live (live‑dead Aqua negative) cell population, as percentage of all singlet cells. Treatment with R848 and higher mRNA vaccine doses drives 
decreased cell viability and recovery. b Dose‑dependent maturation effect from the mRNA vaccine in APCs, as demonstrated by up‑regulation of 
HLA‑DR. c Dose‑driven activation of APCs, as demonstrated by up‑regulation of CD86. d Activation of B‑cells, as demonstrated by up‑regulation of 
CD86. e, f cytokine production in response to TLR7/8 stimulus (R848, 5 μg/ml) and the mRNA vaccine. The mRNA vaccine was dosed at the µg con‑
centration listed per million cells (ex. 5 μg/106 cells). Mean ± SEM are shown for n = 24 subjects examined in MIMIC® modules. Statistical analysis 
was performed with GraphPad Prism software (version 6.04) using Dunnett’s multiple comparisons test. p value indicators ns, *, and **** refer to “no 
significant correlation”, p < 0.05, p < 0.0001, respectively
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Fig. 2 Innate response in MIMIC®‑PTE immune cell populations. a Number of differentially regulated transcripts relative to the respective no 
treatment control. Number of up‑ or down‑regulated genes is stated in parentheses, arrows indicate up‑regulated (↑) or down‑regulated (↓) genes. 
Transcriptional response to the mRNA vaccine (RNActive®) showed strong correlation to the TLR 7/8 agonist R848. Correlation between the mRNA 
vaccine and R848 (correlation plot) in (b) all 50,000+ gene transcripts (whole transcriptome), c all differentially expressed genes and d in the 
immune‑related gene subset that includes the following gene subsets: chemokines, cytokines, antigen presentation, mannose receptors, TLRs, 
CLRs, MHC class 1 and 2, and other miscellaneous immune‑related genes. The mRNA vaccine and R848 trigger comparable transcriptional changes, 
with Pearson’s correlation coefficients above 0.94. e Hierarchical clustering of significant differentially expressed genes in MIMIC®‑PTE samples 
after treatment with no antigen (mock), mRNA vaccine, or R848 treatment. Common up‑regulation and down‑regulation of genes was evident in 
samples treated with mRNA vaccine and R848. Number of donors in each group = 6
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response profile indicated that the mRNA vaccine enters 
the cell through a mechanism that leads to activation of 
receptors in endosomal compartment and the cytoplasm.
MHC class I and II gene activity increased in response 
to treatment with mRNA vaccine, indicating a matura-
tion of the APC cell population (Figs. 1b, 3). Down-reg-
ulation of cd14 transcripts correlated well with this shift 
of phenotype. These results align with the phenotyping 
results indicating APC maturation as evidenced by the 
shift to a CD14low/HLA-DRhigh phenotype (Additional 
file 3: Fig. S3). The phenotyping results indicated that the 
co-stimulatory surface marker CD86 increased substan-
tially in the MIMIC®-PTE population harvested and ana-
lyzed after 24 h (Fig. 1c). However, at this time point cd86 
gene activity dropped in the mRNA vaccine treated cells 
versus no antigen control.
Chemokine and cytokine patterns of induction follow-
ing treatment with the mRNA vaccine were similar as 
evidenced by the increased expression of several markers 
of innate immune cell activation by TLR ligands includ-
ing IL-12(p40), IL-12(p70), IFN-α, and TNF-α (Fig.  1e, 
f; Additional file  5: Fig. S5). Enhanced expression of 
Fig. 3 Administration of the mRNA vaccine induces multiple genes of innate immunity in MIMIC®‑PTE immune cell populations. Transcriptional 
response to the mRNA vaccine is compared with R848. The 86 genes shown were taken from the subset of genes designated as immune‑related. 
The heat map represents normalized mean expression values depicted as log2 fold change relative to the respective buffer control. Transcripts were 
grouped by their immune function. Number of donors in each group = 6
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cytokines and chemokines correlated with increased 
cytokine/chemokine related gene activity (Fig.  3). An 
exception to this was the lack of increased gene activ-
ity corresponding to increased levels of IL-6 and IL-8. 
In the MIMIC® TW-PTE increases in IL-6 and IL-8 are 
driven primarily by the endothelial cell population (data 
not shown). Because the transcriptome analysis was per-
formed only on the immune cell population which was 
physically separate from the endothelial cells, up-regu-
lation of il-6 and il-8 was not expected to be observed. 
One glaring difference between the mRNA vaccine and 
R848 was seen in the induction of il-27. il-27 induction 
was down-regulated from the mRNA vaccine and signifi-
cantly up-regulated by R848. This cytokine is reported to 
promote CD4+ T cell differentiation to the T helper (Th) 
1 lineage and suppresses Th2 and Th17 differentiation 
and to promote type 1 regulatory (Tr1) which produce 
IL-10 [54, 55].
The most significant human immune pathways induced 
following stimulation with the mRNA vaccine include 
those associated with the TLR, IL-1, and JNK (c-jun 
N-terminal kinases) pathways (Additional file 6: Fig. S6). 
IL-1 and JNK are part of the NF-κB and mitogen-acti-
vated protein kinase (MAP kinase) signaling pathways, 
activation pathways into which PRRs converge to trans-
duce signals.
Multiple innate‑associated genes are induced in mice 
following ID administration of mRNA vaccine
The third phase of this study was performed in C57BL/6 
mice to assess the mechanisms of self-adjuvantation of 
mRNA vaccines in vivo. The mRNA vaccine was applied 
via intradermal injection, distributed evenly between two 
sites on the backs of C57BL/6 mice. Biopsies were col-
lected 6 or 24  h post-treatment from the injection site 
(two approx. 1 cm2 pieces per mouse) and the dLN (axil-
iary and brachial, four dLN in total) were collected. Both 
cellular and molecular sensors at the injection site and in 
the draining lymph nodes were evaluated for phenotype, 
chemokine production, and gene expression patterns. As 
shown in Fig. 4a numerous transcripts (>1000) were dif-
ferentially regulated in the skin early following mRNA 
vaccine treatment. Changes in the gene expression after 
treatment were also detected in the dLN, however the 
number of differentially regulated transcripts was clearly 
lower here than observed in the skin samples.
Administration of the mRNA vaccine led to significant 
transient induction of distinct chemokines, cytokines and 
activation markers of immune cells locally at the injection 
site. Among the chemokines the CXC chemokine recep-
tor (CXCR) 3-ligands CXCL9, CXCL10 and CXCL11 
whose pleiotropic functions include stimulation of mono-
cytes/macrophages, T cells, NK cells, and dendritic cell 
migration showed the most pronounced up-regulation 
(Fig. 4b, c left panel). The gene expression level of CCL5, 
a chemokine that selectively supports the migration of 
CD4-expressing monocytes and T lymphocytes was also 
strongly elevated. This coincided with up-regulated gene 
expression of CCR5, the receptor of CCL5 (Fig.  4c, left 
panel). Pro-inflammatory cytokines IL-6, TNF-α as well 
as IL-27, a heterodimeric cytokine belonging to the IL-12 
family were increased early upon vaccine administration. 
In addition, elevated gene expression of CD69, CD40 and 
CD86 was detected early upon mRNA vaccine treatment 
indicating specific activation of immune cells in the skin 
(Fig. 4c). CD86 up-regulation suggests activation of anti-
gen presenting cells. Of note, the key regulator of MHC 
class I-dependent immune responses NLRC5 along with 
several components of the MHC class I antigen pro-
cessing and presentation pathway showed elevated gene 
expression in the skin early upon mRNA vaccine injec-
tion (Fig. 4c, left panel).
ID mRNA vaccine injection in mice induces multiple genes 
of innate immunity in the dLN
In general, a similar profile of the changes in gene expres-
sion as described for the skin was observed in the dLN. 
However, compared to the skin, the intensity of the up-
regulation of the expression of certain genes was slightly 
weaker and several factors such as CCL5, IL- 6, TNF-α, 
apoptosis-related genes and some inflammasome com-
ponents were not elevated in the dLN (Fig.  5a). IFN-α6 
and IFN-γ which were not detected in the skin showed 
augmented gene expression in the dLN following mRNA 
vaccine treatment (Fig.  5a, right panel). Single cell sus-
pensions from the dLNs were analyzed using polychro-
matic flow cytometry gating on live cells followed by 
staining for markers of immune cell activation. Up-regu-
lation of CD86 was detected in both migratory dendritic 
cells and B cells (Fig. 5b, c). Administration of the mRNA 
vaccine induced dose-dependent activation of dendritic 
cells and B cells in the dLN 24 h post treatment.
Correlation and differences in innate response to mRNA 
vaccine between human (MIMIC®) and mice
Analyses of the receptors that play a role in the rec-
ognition of the mRNA vaccine by the innate immune 
system revealed that cytoplasmic RNA sensors of the 
retinoic acid-inducible gene (RIG)-I-like receptor family 
such as RIG-I and MDA-5 as well as the positive regu-
lator of RIG-I- and MDA-5-mediated response, LGP-2 
were elevated early upon mRNA vaccine administration 
in the injection site and in the human MIMIC®-PTE 
(Fig. 4c). Additionally, the gene expression of the RING-
finger E3 ubiquitin ligase TRIM25 which induces the Lys-
linked ubiquitination of RIG-I and is therefore crucial 
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Fig. 4 mRNA vaccine induced multiple genes of innate immunity at the injection site, in the dLN in mice, and in the human MIMIC®. C57BL/6 mice 
were treated via the ID route with the indicated amount of mRNA vaccine distributed to two injection sites on the back of the mice. a Number of 
differentially regulated transcripts relative to the respective buffer control. Number of up‑ or down‑regulated genes is stated in parentheses, arrows 
indicate up‑regulated (↑) or down‑regulated (↓) genes. Administration of mRNA vaccine increased the gene expression in the skin 6 h post admin‑
istration of mRNA vaccine RNA was isolated from RNAlater‑preserved skin biopsies collected 6 or 24 h post ID application of the mRNA vaccine. b 
Increase of the gene expression of CXCR3‑ligands in the skin 6 h post administration of the mRNA vaccine. The dots indicate the signal intensity of 
each sample, cross-bar corresponds to the mean value. The groups compared with each other are highlighted. c RNA was isolated from RNAlater‑
preserved skin biopsies collected 6 or 24 h post ID application of the mRNA vaccine. The Heat map represents normalized mean expression values 
depicted as log2‑fold change relative to the respective buffer control. Transcripts were grouped by their immune function. Heat maps representing 
transcriptional changes in MIMIC® immune cell populations collected 24 h after treatment with mRNA vaccine were included for comparison
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for RIG-I-mediated activity was also up-regulated early 
in the injection site. This contrasts with down-regula-
tion of this gene in the MIMIC® that may be due to the 
evaluation of these samples 24 h after treatment or spe-
cies-specific differences in mRNA vaccine-induced cell 
activation. Data from the murine skin samples supports 
the possibility of a temporal parameter since a similar 
down-regulation was observed in the mouse injection 
site samples 24  h after treatment. The helicase Ddx60 
that promotes the binding of RIG-I to dsRNA showed 
increased gene expression in both the MIMIC® and the 
mouse injection site. Taken together, our analyses indi-
cate that RIG-I-like receptor-mediated signaling network 
participates in the sensing of the administered mRNA 
Fig. 5 mRNA vaccine induced multiple genes of innate immunity in the dLN. RNA was isolated from RNAlater‑preserved LN biopsies (axillar and 
brachial) collected 6 or 24 h post ID application of mRNA vaccine. Whole genome expression analysis was performed using Affymetrix WT Mouse 
Gene‑2.1‑ST GeneChip Array. a Heat map represents normalized mean expression values depicted as log2 fold change relative to the respective 
buffer control. Transcripts were grouped by their immune function. b, c dLN (axillar, brachial and inguinal) were harvested 24 h post treatment and 
single cell suspensions were analyzed using polychromatic flow cytometry gating on live cells by followed by staining for markers of (b) migra‑
tory dendritic cells (CD11c+MHCIIhigh cells) and (c) B cells (B220+CD19+ cells). The surface expression of CD86 on dendritic cells and B cells was 
determined as geometric mean fluorescence intensity (GMFI). Mean ± SEM are shown for n = 8 mice per group. Statistical analysis was performed 
with GraphPad Prism software (version 5.04) using Kruskal–Wallis test followed by Dunns multiple comparison test. p value indicators ***, **, * refer 
to p < 0.05, p < 0.01 and p < 0.001, respectively
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vaccine in the skin of the mouse and the human MIMIC® 
(Fig.  6), with common up-regulation of genes demon-
strated in both species.
Besides the RLRs, Toll-like receptors and NOD-like 
receptors (NLR) also showed differential gene expression 
upon mRNA vaccine treatment. The endosomal RNA 
receptors TLR3 and TLR7 were up-regulated with TLR3 
showing enhanced expression levels early in the injec-
tion site (6 h) and in the human MIMIC®. While TLR7 
increases were detected in the MIMIC® sample, TLR7 
increase was only detected in the late (24 h) sample fol-
lowing mRNA vaccine treatment in the mouse (Fig. 4c). 
The up-regulation of TLR9 in the injection site of the 
mouse, which is not a RNA-sensor but recognizes spe-
cific unmethylated CpG motifs prevalent in microbial 
genomic DNA can most probably be explained as an 
unspecific bystander effect mediated by the local pro-
inflammatory milieu induced by the mRNA vaccine. 
Notably, the gene expression of several components of 
the inflammasome signaling pathway such as AIM2, 
NOD-1, caspase-1 and caspase-4 was also increased 
6  h after mRNA vaccine injection in the mouse and in 
human MIMIC®-PTE modules.
Further evaluation was performed on the genes of 
innate immunity listed in Fig.  3 to correlate transcrip-
tional response between the human (MIMIC®-PTE) 
and the mouse. In the mouse, four data sets were eval-
uated: 6 and 24  h injection site (skin), 6 and 24  h dLN. 
Transcriptional response to the mRNA vaccine showed 
a moderately positive correlation in innate response 
between human MIMIC® and mouse injection site 6  h 
after injection, with an R value of 0.6036 (Fig.  7a). This 
correlation is lost between MIMIC and the 24 h injection 
site sample. Between the MIMIC® and the dLN correla-
tion in transcriptional response improved between 6 and 
24 h, but overall limited correlation is observed Fig. 7b. 
This loss of correlation from the 6 and 24 h skin biopsy 
and MIMIC® with simultaneous improvement in cor-
relation from the 6 and 24 h dLN samples and MIMIC® 
could indicate migration of the activated innate immune 
population from the site of injection to the lymph node. 
Species-specific differences and limitations to the in vitro 
Fig. 6 Analysis of RIG‑I (encoded by Ddx58 gene) signaling network after mRNA vaccine treatment in humans (MIMIC®) and mice. a RNA generated 
from MIMIC®‑PTE immune cell populations 24 h after modules were treated with the mRNA vaccine. b The mRNA vaccine was injected into mice, 
and 6 h post administration RNA was isolated from RNALater‑preserved skin biopsies. Up‑regulated genes are shown in red, solid lines indicate direct 
interactions, dashed lines indirect effects, arrow heads indicate causality
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model could also account for less than perfect correlation 
between the samples.
Discussion
In this study, we evaluated the innate immunostimula-
tory potential of an mRNA vaccine encoding influenza 
A hemagglutinin, a vaccine that previously demonstrated 
protective immunity to influenza A virus infections in 
mice and pigs [45]. This evaluation was performed in an 
in  vitro model of human innate immunity and in  vivo 
in mice after intradermal injection. To evaluate the self-
adjuvant properties of this novel vaccine a translational 
approach was undertaken to correlate phenotypic and 
cytokine/chemokine responses in immune cell popula-
tions to transcriptional responses in those same cells. 
In the human MIMIC® strong correlation was dem-
onstrated in phenotypic, cytokine, and transcriptional 
response between the TLR7/8 agonist R848 and the 
mRNA vaccine indicating that at least a part of the sign-
aling involved these TLR receptors. However, there were 
some noteworthy differences in transcript up-regulation. 
Both il-27 and il-8 were down-regulated following treat-
ment with mRNA vaccine and up-regulated by R848. 
ddx58 (RIG-1), ifih1 (MDA-5), and tlr3 were all up-regu-
lated by the mRNA vaccine to a much greater degree than 
from R848. These differences support the notion that the 
vaccine does not act solely through stimulation of the 
TLR7/8 pathway. The adjuvant effect of mRNA vaccine in 
humans (MIMIC®) and mice acts through similar cellular 
RNA sensors found in endosomal compartments as well 
as within the cytoplasm of immune cells. Transcriptional 
analysis demonstrated up-regulation of TLR3, 7, and 8 in 
humans, TLR 3 and 7 in mice, and RLRs such as RIG-I, 
MDA-5, and inflammasome components in both spe-
cies. Sixty-five of the 81 “innate” immune-related genes 
identified in this study demonstrated correlative tran-
scriptional regulation in human MIMIC® modules and at 
the injection site in mice 6  h after treatment. The most 
significant immune pathways induced in response to the 
mRNA vaccine include the TLR, IL-1, and JNK pathways. 
Results from the phenotypic analysis of immune cell pop-
ulations and cytokine/chemokine levels of treated human 
MIMIC® modules and ID injected mice confirmed the 
immunostimulatory capacity of the mRNA vaccine. Phe-
notyping revealed immune cell maturation and activation 
of APCs and B-cells. Cytokine/chemokine analysis indi-
cated production of factors in both systems that could 
attract and activate key players of the innate and adaptive 
immune system.
Similarities and differences have been demonstrated 
between mice and humans in immune system devel-
opment, activation, and response to challenge [2–6]. 
The relevance of any study in mice into the effects that 
immunostimulatory agents and adjuvants to the human 
response depends upon whether those stimuli target 
pathways that are conserved or convergent between 
Fig. 7 Correlation plot for human MIMIC® and murine response in the immune‑related gene subsets listed in Figs. 3 and 4. a MIMIC® versus 6 and 
24 h injection site transcripts, b MIMIC® versus 6 and 24 h dLN transcripts. Response was most correlative between MIMIC®‑PTE and 6 h injection 
site innate response, as evaluated with second order polynomial fit (quadratic). R values are listed
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mice and humans and whether it is realistic to single out 
particular genes for analysis. In this study the focus was 
on predicting the innate response in humans following 
treatment with an mRNA vaccine using two model sys-
tems, a human in vitro model and a murine model. The 
mRNA vaccine largely drove consistent responses in 
the two despite some species-specific differences in cell 
populations, differences in RNA sensors between the 
species, and fundamental differences between in  vitro 
models and in  vivo testing. When comparing mice and 
humans, some differences have been noted in the prin-
ciple ssRNA sensors present in immune cell populations. 
In mice, dendritic cells typically express TLR7 whereas in 
humans TLR8 is present on myeloid-derived DCs (which 
predominate in our system) while TLR7 can be found 
on plasmacytoid DCs and B-cells (subsets also found in 
the MIMIC®) [31, 32, 56]. Based on the transcriptional 
profile measured in both humans and mice, genes for 
RLRs [ddx58 (RIG-1) and ifih1 (MDA-5)], TLRs (tlr3, 
tlr7, and tlr8-human only), and CLRs (clec4gp1, clec2d, 
cledl1) were all significantly up-regulated by the mRNA 
vaccine. The up-regulation of TLR8 and TLR7 points to 
the involvement of both mDCs and pDCs in the innate 
response to the mRNA vaccine in humans. The induced 
production of IFNα from the mRNA vaccine suggests 
that pDCs present in MIMIC® were activated. TLR3 
and RLRs were activated in the mouse and the human 
MIMIC ® indicating the probability of double-stranded 
structure in the mRNA vaccine that effectively amplifies 
the adjuvant effect of the vaccine. These endosomal and 
cytoplasmic sensors of dsRNA do not typically respond 
to R848 and while gene families for both are up-regu-
lated slightly by R848 the mRNA vaccine triggered much 
greater up-regulation of these sensors and activation of 
relevant downstream pathways. This overlap of results 
between the mouse and human models highlight the rel-
evance of each for studying a subset of conserved gene 
families when evaluating the adjuvant effects of this vac-
cine. The models complement each other to highlight 
receptors that are conserved between species and known 
to generate innate responses following challenge with 
RNA. In some cases, however, transcriptional differences 
were observed between the mouse and human, likely due 
to different patterns of cellular sensors on innate immune 
cell populations. The gene for il-27 is up-regulated early 
in the injection site but is down-regulated late in the 
injection site and in the MIMIC® possibly due to dif-
ferences in the pattern of response between the mouse 
and human, specifically in TLR7/8 activation. This is 
supported by the up-regulation of il-27 in the MIMIC® 
from R848 which activates TLR7 but down-regulation 
from the mRNA vaccine which appears to activate TLR8 
in mDCs.
In addition to consistent transcriptional responses 
between the mice and the human subjects evaluated in 
this study, mRNA vaccination resulted in phenotypic and 
cytokine/chemokine responses that were similar between 
the two species and reflected the transcriptional profile. 
Elevated expression of genes for CD69 and CD40 was 
detected early upon mRNA vaccine injection in mice 
indicating specific activation of immune cells in the 
skin. Increased surface expression of CD86 was meas-
ured in human MIMIC®-PTE APCs and B-cells and also 
in migratory dendritic cells and B-cells in the draining 
lymph nodes of mice, all suggesting activation of antigen 
presenting cells. However in the PTE module at this time 
point cd86 gene activity dropped in the mRNA vaccine 
treated cells versus no antigen control. This decline may 
have been due to an initial burst in cd86 activity followed 
by a subsequent decline since the dose used in the tran-
swell experiments (25 μg) was higher than that showing 
optimal immune cell activation on the APC population 
from the PTE (10 μg). Another possibility to explain the 
discrepancy between phenotype and gene expression 
of CD86 is that there exists an intracellular reservoir of 
CD86 in dendritic cells [57]. These intracellular reser-
voirs can cycle CD86 to the cellular membrane rapidly 
in response to cell activation. mRNA vaccine mediated 
cell activation may trigger this cycling with no require-
ment for gene activation. Transcript analysis at a time 
point earlier than 24 h would help to elucidate the kinet-
ics of the cd86 gene. In contrast to cd86, the transcrip-
tional response profiles for CD14, CD40, and CCR7 
following treatment with the mRNA vaccine matched the 
protein expression profiles detected by flow cytometry 
in the PTE derived cells. Administration of the mRNA 
vaccine also led to significant induction of chemokines 
and cytokines locally at the injection site in mice and in 
MIMIC®-PTE modules. In the mice, the CXCR3-ligands 
CXCL9, CXCL10 and CXCL11 whose pleiotropic func-
tions include stimulation of monocytes/macrophages, T 
cells, NK cells, and dendritic cells migration showed the 
most pronounced up-regulation among the chemokines, 
up-regulation that was reflected in the transcriptional 
analysis of human MIMIC® modules. In the human 
MIMIC® sentinel markers for immune cell activation 
were all up-regulated, including IL-12(p40), IL-12(p70), 
IFN-α, and TNF-α.
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When comparing responses to the mRNA vaccine 
between MIMIC®-PTE modules and mice after intrader-
mal injection there is a fundamental difference between 
the two that must be addressed. After innate stimulation 
immune cells and specifically dendritic cells in vivo cap-
ture and process antigen, mature and are activated, and 
migrate to the lymph node to prime the adaptive immune 
system. Consequently the gene signature of activation 
will gradually be lost in the injection site and appear in 
the draining lymph node. In the MIMIC® immune cells, 
which consist primarily of antigen presenting cells, 
respond to stimuli like mRNA vaccines to activate and 
mature in place because migration is not possible in this 
system. When evaluating the MIMIC®-PTE modules 
responding APCs are examined 24  h after treatment. 
Consequently MIMIC®-PTE modules may demonstrate 
innate response characteristics found in both the skin 
and in the dLN of the mouse model. Overall, however, 
while there is some correlation between the MIMIC® 
dataset and the mouse datasets, specifically the injection 
site 6 h post-injection and the dLN 24 h post injection, 
differences are evident and may be driven by the species 
tested, the in vitro versus in vivo models, or unidentified 
reasons.
Conclusions
The translational approach used in this pre-clinical 
assessment into the basic mechanisms of self-adjuvanta-
tion from the mRNA vaccine allowed the identification of 
the mechanism of action by which the vaccine exerts its 
effect in humans and mice. In both species the vaccine 
acts through cellular RNA sensors, driving maturation 
and activation of immune cells as well as production of 
cytokines and chemokines known to attract and activate 
key players of the innate and adaptive immune system. 
In addition, because this approach could simultane-
ously be applied to both the in vitro human MIMIC® and 
in vivo mouse studies, correlative or divergent responses 
between the two species and two types of models were 
identified. Based on consistency between the two species 
in phenotypic, cytokine/chemokine, and transcriptional 
response to mRNA vaccine treatment, the mechanism 
of action of the adjuvant activity of this mRNA vaccine 
appears to be relatively conserved or at least conver-
gent between the two species indicating that the innate 
immune stimulation from mRNA vaccines seen in mice 
translates to the human system. In addition, the results 
demonstrate that the MIMIC® system can be useful in 
preclinical evaluations of innate immune response to 
mRNA vaccines, with the potential identification of rele-
vant pathways only evident in humans while demonstrat-
ing great similarity in the overall activation profile found 
in mouse studies.
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